|
Post by sluggobear on Feb 1, 2017 23:17:35 GMT -5
I think it's just two things. Because Mike is involved and the uptick in Sales Force personnel is happening there will be discussion of that. Number 2, I think it's a slam dunk that there will be a reverse split. There's no way that can wait any longer. While a reverse split seems like a big blow and it can be, I bought Lexicon right before a reverse split. The stock LXRX has doubled since then and I think it was important to stay listed on the NASDAQ. I also found one article which looked at historical performance after RS for about 15-20 companies. It was generally positive for the large majority of them. Sluggobear, you nailed it perfectly!!!! Thanks but I think I was stating the obvious. IMO MannKind management is playing Afrezza too conservative. Instead of the traditional approach for getting traction, they should have considered they would need a creative disruptive approach for a disruptive product. There must be examples of case studies? Tesla comes to mind; but examples in pharma? They should have identified the top three barriers to sales success and had strategies in place years ago to knock them down or get around them. And if these barriers looked impenetrable, as they have looked to me for the last 2 years, why not consider/try something creative? It seems the traditional insurance payor/PBM approach for coverage has not been fruitful. Given the limited runway time that they had, which is now coming to an end, my suggestion was that they low-ball the price to bypass insurance. Optimize advertising thru news that Mannkind was sticking it to the big 3 insulin pharmas by undercutting all their prices. This commentary belongs in another thread I guess. I am so far underwater that what I have left is not worth selling but at some point you do give up all hope unfortunately. I really think they need to do something big and splashy even if it looks desperate because I don't think the alternative (stay the course) approach will make it.
|
|